| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Chowell, Diego |
| dc.contributor.author | Martínez-Jiménez, Francisco |
| dc.date.accessioned | 2025-04-22T07:53:37Z |
| dc.date.available | 2025-04-22T07:53:37Z |
| dc.date.copyright | 2024 |
| dc.date.issued | 2025-04 |
| dc.identifier.citation | Martínez-Jiménez F, Chowell D. Genetic immune escape in cancer: timing and implications for treatment. Trends in Cancer. 2025 Apr;11(4):286–94. |
| dc.identifier.issn | 2405-8025 |
| dc.identifier.uri | http://hdl.handle.net/11351/12971 |
| dc.description | Immunotherapy resistance; Tumor evolution; Tumor microenvironment |
| dc.description.abstract | Genetic immune escape (GIE) alterations pose a significant challenge in cancer by enabling tumors to evade immune detection. These alterations, which can vary significantly across cancer types, may often arise early in clonal evolution and contribute to malignant transformation. As tumors evolve, GIE alterations are positively selected, allowing immune-resistant clones to proliferate. In addition to genetic changes, the tumor microenvironment (TME) and non-genetic factors such as inflammation, smoking, and environmental exposures play crucial roles in promoting immune evasion. Understanding the timing and mechanisms of GIE, alongside microenvironmental influences, is crucial for improving early detection and developing more effective therapeutic interventions. This review highlights the implications of GIE in cancer development and immunotherapy resistance, and emphasizes the need for integrative approaches. |
| dc.language.iso | eng |
| dc.publisher | Elsevier |
| dc.relation.ispartofseries | Trends in Cancer;11(4) |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Càncer - Immunoteràpia |
| dc.subject | Càncer - Aspectes genètics |
| dc.subject | Resistència als medicaments |
| dc.subject.mesh | Neoplasms |
| dc.subject.mesh | /therapy |
| dc.subject.mesh | Drug Resistance, Neoplasm |
| dc.subject.mesh | Tumor Escape |
| dc.subject.mesh | Immunotherapy |
| dc.title | Genetic immune escape in cancer: timing and implications for treatment |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1016/j.trecan.2024.11.002 |
| dc.subject.decs | neoplasias |
| dc.subject.decs | /terapia |
| dc.subject.decs | resistencia a los antineoplásicos |
| dc.subject.decs | escape del tumor |
| dc.subject.decs | inmunoterapia |
| dc.relation.publishversion | https://doi.org/10.1016/j.trecan.2024.11.002 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Martínez-Jiménez F] Systems Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Hartwig Medical Foundation, Amsterdam, The Netherlands. [Chowell D] The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| dc.identifier.pmid | 39632211 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |